FLT3 and gastrointestinal stromal tumor: Unlike other AML treatments, quizartinib has not been studied extensively due to its limited efficacy on solid tumors, which harbor few genetic mutations in FLT3, with the exception of gastrointestinal stromal tumors (GISTs), which harbor gain-of-function mutations in the KIT receptor.